Schmidinger M, et al. - In this study with 657 patients with advanced renal cell carcinoma (RCC), researchers aimed to corroborate the real-world safety and efficacy of pazopanib in the PRINCIPAL study. To qualify for the study, patients were required to have clear cell advanced/metastatic RCC and had decided to start pazopanib treatment within 30 days of enrollment. Patients were given ≥1 dose of pazopanib. The estimated median progression-free survival was 10.3 months and overall survival was 29.9 months, with an objective response rate of 30.3%. Little or no decline in health-related quality of life was evident over time. A total of 64 (9.7%) patients experienced treatment-related serious adverse events (AEs) and 399 (60.7%) suffered AEs of special interest. Overall, pazopanib was proved as efficacious and safe in patients with advanced/metastatic RCC in a real-world clinical setting.